Clinical Scorecard: Unlocking the Supraciliary Space
At a Glance
| Category | Detail |
|---|---|
| Condition | Glaucoma |
| Key Mechanisms | Targeting uveoscleral outflow to reduce intraocular pressure (IOP) |
| Target Population | Patients with primary open-angle glaucoma (POAG) |
| Care Setting | Ophthalmology clinics and surgical centers |
Key Highlights
- Supraciliary MIGS devices offer a less invasive alternative to traditional glaucoma surgeries.
- The iStent Supra and MINIject are notable devices targeting the supraciliary space.
- The CyPass microstent was withdrawn due to safety concerns related to endothelial cell loss.
Guideline-Based Recommendations
Diagnosis
- Evaluate IOP and assess for glaucoma progression.
Management
- Consider MIGS for patients not adequately controlled by medical therapy or laser treatment.
Monitoring & Follow-up
- Regular follow-up to assess IOP and potential complications post-surgery.
Risks
- Be aware of potential complications such as hypotony and endothelial cell loss.
Patient & Prescribing Data
Pseudophakic subjects aged ≥46 years with medically uncontrolled POAG.
MIGS devices like MINIject have shown significant IOP reduction with fewer medications required.
Clinical Best Practices
- Utilize gonioscopy for accurate placement of MIGS devices.
- Monitor endothelial cell density postoperatively, especially with devices like CyPass.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
